Title

Inhaled Levodopa (CVT-301) for Treatment of off Periods in Parkinson's Disease: Efficacy as Assessed by 39-Item Parkinson's Disease Quality of Life (QoL) Questionnaire

Document Type

Conference Proceeding

Publication Date

8-2019

Publication Title

J Mov Disord

Abstract

Objective: Pre-specified and post-hoc analyses investigated QoL changes as assessed by the 39-item Parkinson's Disease Questionnaire (PDQ-39) over the 12-week period of a phase 3 study (SPAN-PD) and its correlation with changes in Patient Global Impression of Change (PGIC). Background: Inbrija (CVT-301) is a levodopa inhalation powder developed for the intermittent treatment of OFF episodes in patients on a carbidopa/levodopa regimen. In the SPAN-PDSM study, CVT-301 84mg significantly improved motor function in patients experiencing OFF periods, as measured by lower UPDRS-III scores 30 minutes post-dose, evaluated at 12 weeks. Positive treatment effect was observed in PGIC. Methods: This was a 12-week study of PD patients experiencing motor fluctuations on a standard oral carbidopa/levodopa regimen. Patients were randomized to placebo, CVT-301 60mg or 84mg (1:1:1) for the treatment of OFF period symptoms as needed up to 5 times/day. PDQ-39 and PGIC were completed at baseline, 4, 8, and 12 weeks. A post-hoc analysis using an anchor-based approach examined the change in PDQ-39 domains (mobility and activities of daily living [ADL]). The PGIC (scored from 1["much improved"] to 7["much worse"]) was used as anchor for the 12-week study period. Results: Improvement in PDQ-39 ADL and mobility was linked to the minimum improvement in PGIC ("a little improved") with estimated changes of-1.979(P=0.01) for ADL and-1.335(P=0.06) for mobility scores when the 3 treatment arms were pooled. Estimated treatment differences vs placebo for the CVT-301 84-mg dose were-2.08, for ADL, and-2.19 for mobility. For both doses, treatment differences in ADL and mobility were above the estimates correlating with minimum improvement in PGIC. Conclusions: Patients treated with CVT-301 showed more improvement in ADL and mobility as assessed by PDQ-39 which correlated with improvement in PGIC as compared with placebo-treated patients at 12 weeks. Maintaining independence in ADL helps optimize QoL for PD patients.

Volume

34

First Page

S7

Last Page

S8

This document is currently not available here.

Share

COinS